Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
This study is currently recruiting participants.
Study NCT00561418 Information provided by National Cancer Institute (NCI)
First Received: November 20, 2007 Last Updated: March 27, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Small Intestine Cancer
Additional conditions recognized in this trial
Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
vorinostat
DNA analysis
immunologic technique
laboratory biomarker analysis
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Arthur G. James Cancer Hospital &Richard J. Solove Research Institute
National Cancer Institute (NCI)
Back to top of Main Content
